Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INCACAD · Entity 3913 | PRINCIPAL ACCOUNTING OFFICER | June 26, 2026 | June 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACADIA PHARMACEUTICALS INC
Report date June 26, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,088 |
Reported balance
After 2026-06-26 transaction · row 1
1 source rowRow 1 · 2026-06-26 · Sale · Disposed 11,421 · Balance 13,088 F1: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 9, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.88 to $26.265, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
Filing footnotes · ownership attribution and instrument terms
F1: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 9, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.88 to $26.265, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 05, 2024 Filed Apr 9, 2024 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 2,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-010602 · form4-04092024_060403.xml · derivative · entry 5 Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,020 Underlying: Common Stock · 2,010 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023. F5 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023. Read SEC document |
| April 05, 2024 Filed Apr 9, 2024 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 2,010 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-010602 · form4-04092024_060403.xml · nonDerivative · entry 1 Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,401 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 25, 2024 Filed Mar 28, 2024 00:02 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 8,568 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-009273 · form4-03282024_120355.xml · derivative · entry 2 Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,568 Underlying: Common Stock · 8,568 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning March 25, 2025. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning March 25, 2025. Read SEC document |
| March 25, 2024 Filed Mar 28, 2024 00:02 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Options (Right to Buy) · Derivative | 13,964 | $0.00 Strike: $17.84 | $0.00 |
DisclosureSEC source: 0001415889-24-009273 · form4-03282024_120355.xml · derivative · entry 1 Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,964 Underlying: Common Stock · 13,964 shares Expires 2034-03-24 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on March 25, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| February 26, 2024 Filed Feb 27, 2024 23:07 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 474 | $24.67 | $11,693.58 |
DisclosureSEC source: 0001415889-24-005574 · form4-02272024_110201.xml · nonDerivative · entry 2 Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,391 F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 23:07 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 840 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-005574 · form4-02272024_110201.xml · derivative · entry 3 Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 840 Underlying: Common Stock · 840 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 23, 2022. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 23, 2022. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 23:07 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 840 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-005574 · form4-02272024_110201.xml · nonDerivative · entry 1 Kihara James · CIK 0001816160 · PRINCIPAL ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,865 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 15, 2023 Filed Dec 16, 2023 00:37 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 2,000 | $28.30 | $56,600.00 |
DisclosureSEC source: 0001209191-23-058891 · doc4.xml · nonDerivative · entry 1 Kihara James · CIK 0001816160 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,025 F1 · kind: The sales reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Read SEC document |
| November 20, 2023 Filed Nov 21, 2023 23:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 1,985 | $22.64 | $44,940.40 |
DisclosureSEC source: 0001209191-23-056354 · doc4.xml · nonDerivative · entry 3 Kihara James · CIK 0001816160 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,025 F3 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.615 to $22.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| November 17, 2023 Filed Nov 21, 2023 23:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 1,982 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-056354 · doc4.xml · derivative · entry 5 Kihara James · CIK 0001816160 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,931 Underlying: Common Stock · 1,982 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period. F6 · derivative.expiration_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period. Read SEC document |
| November 17, 2023 Filed Nov 21, 2023 23:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 1,982 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-056354 · doc4.xml · derivative · entry 4 Kihara James · CIK 0001816160 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,931 Underlying: Common Stock · 1,982 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. F5 · derivative.expiration_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. Read SEC document |
| November 17, 2023 Filed Nov 21, 2023 23:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 1,982 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-056354 · doc4.xml · nonDerivative · entry 2 Kihara James · CIK 0001816160 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,010 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 17, 2023 Filed Nov 21, 2023 23:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 1,982 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-056354 · doc4.xml · nonDerivative · entry 1 Kihara James · CIK 0001816160 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,028 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 268 shares of the Issuer's common stock acquired by the reporting person on November 15, 2023 pursuant to an employee stock purchase program. Read SEC document |
| September 15, 2023 Filed Sep 19, 2023 22:31 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 2,000 | $25.88 | $51,760.00 |
DisclosureSEC source: 0001209191-23-050072 · doc4.xml · nonDerivative · entry 1 Kihara James · CIK 0001816160 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,778 F1 · kind: The sales reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. F2 · balance_after: Includes an aggregate of 3,611 shares acquired by the Reporting Person under the Issuer's 2004 Employee Stock Purchase Plan on November 13, 2020, May 14, 2021, November 15, 2021, May 13, 2022, November 15, 2022 and May 15, 2023. F3 · balance_after: Includes 23 shares purchased by the Reporting Person in open market transaction on November 21, 2020, with a purchase price of $43.01 per share. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 20:38 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 2,000 | $24.15 | $48,300.00 |
DisclosureSEC source: 0001209191-23-037932 · doc4.xml · nonDerivative · entry 1 Kihara James · CIK 0001816160 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,144 F1 · kind: The sales reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Read SEC document |
| May 17, 2023 Filed May 19, 2023 22:54 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 5,947 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-031245 · doc4.xml · derivative · entry 5 Kihara James · CIK 0001816160 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,913 Underlying: Common Stock · 5,947 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period. F4 · derivative.expiration_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period. Read SEC document |
| May 17, 2023 Filed May 19, 2023 22:54 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 5,947 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-031245 · doc4.xml · derivative · entry 4 Kihara James · CIK 0001816160 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,913 Underlying: Common Stock · 5,947 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. F3 · derivative.expiration_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. Read SEC document |
| May 17, 2023 Filed May 19, 2023 22:54 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 5,947 | $22.50 | $133,807.50 |
DisclosureSEC source: 0001209191-23-031245 · doc4.xml · nonDerivative · entry 3 Kihara James · CIK 0001816160 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,144 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| May 17, 2023 Filed May 19, 2023 22:54 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 5,947 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-031245 · doc4.xml · nonDerivative · entry 2 Kihara James · CIK 0001816160 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,091 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. Read SEC document |
| May 17, 2023 Filed May 19, 2023 22:54 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 5,947 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-031245 · doc4.xml · nonDerivative · entry 1 Kihara James · CIK 0001816160 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,144 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. Read SEC document |
| May 01, 2023 Filed May 4, 2023 01:13 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 10,384 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-027203 · doc4.xml · derivative · entry 2 Kihara James · CIK 0001816160 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,384 Underlying: Common Stock · 10,384 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning May 1, 2024. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning May 1, 2024. Read SEC document |
| May 01, 2023 Filed May 4, 2023 01:13 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Options (Right to Buy) · Derivative | 17,131 | $0.00 Strike: $21.75 | $0.00 |
DisclosureSEC source: 0001209191-23-027203 · doc4.xml · derivative · entry 1 Kihara James · CIK 0001816160 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,131 Underlying: Common Stock · 17,131 shares Expires 2033-05-01 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on May 1, 2024. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| April 10, 2023 Filed Apr 12, 2023 01:15 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 523 | $18.14 | $9,487.22 |
DisclosureSEC source: 0001209191-23-024061 · doc4.xml · nonDerivative · entry 2 Kihara James · CIK 0001816160 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,197 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.14 to $18.165, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| April 07, 2023 Filed Apr 12, 2023 01:15 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 1,489 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-024061 · doc4.xml · derivative · entry 3 Kihara James · CIK 0001816160 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,489 Underlying: Common Stock · 1,489 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: 50% of the restricted stock units vest on April 7, 2022 and 25% vest on each of April 7, 2023 and April 7, 2024. F4 · derivative.expiration_date: 50% of the restricted stock units vest on April 7, 2022 and 25% vest on each of April 7, 2023 and April 7, 2024. Read SEC document |
| April 07, 2023 Filed Apr 12, 2023 01:15 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 1,489 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-024061 · doc4.xml · nonDerivative · entry 1 Kihara James · CIK 0001816160 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. Read SEC document |
| April 06, 2023 Filed Apr 8, 2023 00:41 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 701 | $18.16 | $12,730.16 |
DisclosureSEC source: 0001209191-23-023864 · doc4.xml · nonDerivative · entry 2 Kihara James · CIK 0001816160 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,231 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.16 to $18.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| April 05, 2023 Filed Apr 8, 2023 00:41 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 2,009 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023864 · doc4.xml · derivative · entry 3 Kihara James · CIK 0001816160 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,030 Underlying: Common Stock · 2,009 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023. F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023. Read SEC document |
| April 05, 2023 Filed Apr 8, 2023 00:41 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 2,009 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-023864 · doc4.xml · nonDerivative · entry 1 Kihara James · CIK 0001816160 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,932 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 02:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 350 | $18.78 | $6,573.00 |
DisclosureSEC source: 0001209191-23-013471 · doc4.xml · nonDerivative · entry 2 Kihara James · CIK 0001816160 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,923 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| February 23, 2023 Filed Feb 28, 2023 02:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 840 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-013471 · doc4.xml · derivative · entry 3 Kihara James · CIK 0001816160 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,680 Underlying: Common Stock · 840 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 23, 2022. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 23, 2022. Read SEC document |
| February 23, 2023 Filed Feb 28, 2023 02:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 840 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-013471 · doc4.xml · nonDerivative · entry 1 Kihara James · CIK 0001816160 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| April 08, 2022 Filed Apr 12, 2022 00:02 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 1,025 | $27.05 | $27,726.25 |
DisclosureSEC source: 0001209191-22-024064 · doc4.xml · nonDerivative · entry 2 Kihara James · CIK 0001816160 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,433 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| April 07, 2022 Filed Apr 12, 2022 00:02 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 2,977 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-024064 · doc4.xml · derivative · entry 3 Kihara James · CIK 0001816160 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,978 Underlying: Common Stock · 2,977 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: 50% of the restricted stock units vest on April 7, 2022 and 25% vest on each of April 7, 2023 and April 7, 2024. F3 · derivative.expiration_date: 50% of the restricted stock units vest on April 7, 2022 and 25% vest on each of April 7, 2023 and April 7, 2024. Read SEC document |
| April 07, 2022 Filed Apr 12, 2022 00:02 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 2,977 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-024064 · doc4.xml · nonDerivative · entry 1 Kihara James · CIK 0001816160 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,458 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. Read SEC document |
| April 05, 2022 Filed Apr 7, 2022 23:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 8,039 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-023743 · doc4.xml · derivative · entry 2 Kihara James · CIK 0001816160 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,039 Underlying: Common Stock · 8,039 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023. Read SEC document |
| April 05, 2022 Filed Apr 7, 2022 23:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Options (Right to Buy) · Derivative | 13,793 | $0.00 Strike: $25.75 | $0.00 |
DisclosureSEC source: 0001209191-22-023743 · doc4.xml · derivative · entry 1 Kihara James · CIK 0001816160 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,793 Underlying: Common Stock · 13,793 shares Expires 2032-04-05 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on April 5, 2023. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 22:45 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 840 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-013286 · doc4.xml · derivative · entry 3 Kihara James · CIK 0001816160 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,520 Underlying: Common Stock · 840 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 23 2022. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 23 2022. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 22:45 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 359 | $23.80 | $8,544.20 |
DisclosureSEC source: 0001209191-22-013286 · doc4.xml · nonDerivative · entry 2 Kihara James · CIK 0001816160 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 481 F1 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 22:45 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 840 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-013286 · doc4.xml · nonDerivative · entry 1 Kihara James · CIK 0001816160 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 23:36 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 15,860 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-065928 · doc4.xml · derivative · entry 2 Kihara James · CIK 0001816160 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,860 Underlying: Common Stock · 15,860 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period. F3 · derivative.expiration_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 23:36 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 15,860 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-065928 · doc4.xml · derivative · entry 1 Kihara James · CIK 0001816160 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,860 Underlying: Common Stock · 15,860 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F2 · derivative.exercise_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. F2 · derivative.expiration_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. Read SEC document |
| February 23, 2021 Filed Feb 26, 2021 02:48 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 3,360 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-014560 · doc4.xml · derivative · entry 2 Kihara James · CIK 0001816160 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,360 Underlying: Common Stock · 3,360 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 23 2022. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 23 2022. Read SEC document |
| February 23, 2021 Filed Feb 26, 2021 02:48 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Options (Right to Buy) · Derivative | 6,187 | $0.00 Strike: $49.74 | $0.00 |
DisclosureSEC source: 0001209191-21-014560 · doc4.xml · derivative · entry 1 Kihara James · CIK 0001816160 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,187 Underlying: Common Stock · 6,187 shares Expires 2031-02-23 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on February 23, 2022. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.